Department of Medical Microbiology, University of Manitoba , Winnipeg , Manitoba , Canada.
Centre de Recherche en Infectiologie, Centre Hospitalier Universitaire de Québec, Université Laval , Québec City , Québec , Canada.
Hum Vaccin Immunother. 2019;15(10):2264-2268. doi: 10.1080/21645515.2019.1597595. Epub 2019 Apr 23.
Mobile laboratories provide diagnostic capabilities for routine surveillance and patient identification during an outbreak. In either situation, they face many challenges including identification of the appropriate assay(s) to employ, logistical arrangements, and providing for the health and safety of the laboratory staff. Great strides have been made over the last decade in the development of mobile laboratories with assays that require minimal infrastructure and technical experience. This knowledge and expertise have been developed in partnership with many researchers and public health officials who live in regions prone to infectious disease outbreaks. Mobile laboratories should now also be used in the evaluation of novel vaccines and therapeutics in remote locations. Clinical mobile laboratories will include similar diagnostic capabilities as outbreak response mobile labs, but will also include additional point-of-care instruments operated under Good Clinical Practice guidelines. They will also operate rigorous data management plans so that the data collected will satisfy regulatory agencies during the licensure process. Failure to deploy an adequate clinical mobile laboratory when administering a novel biological product in a remote location is a significant limitation to any collected scientific data that could ultimately undermine clinical development and availability of life-saving interventions.
移动实验室可为疫情爆发期间的常规监测和患者识别提供诊断能力。在这两种情况下,它们都面临着许多挑战,包括确定要使用的适当检测方法、后勤安排以及保障实验室工作人员的健康和安全。在过去十年中,移动实验室在开发需要最小基础设施和技术经验的检测方法方面取得了长足的进步。这些知识和专业技术是与许多生活在传染病爆发风险地区的研究人员和公共卫生官员合作开发的。现在,移动实验室也应该用于评估偏远地区新型疫苗和疗法的效果。临床移动实验室将具有与疫情应对移动实验室类似的诊断能力,但也将包括根据良好临床规范操作的其他即时护理仪器。它们还将实施严格的数据管理计划,以便在许可过程中收集的数据满足监管机构的要求。在偏远地区使用新型生物制品时,如果未能部署足够的临床移动实验室,将对可能最终破坏临床开发和挽救生命干预措施的任何收集到的科学数据造成重大限制。